China advances semaglutide biosimilars, Jiuyuan seeks NMPA nod - BioWorld Online
| 000963 Stock | 35.95 0.24 0.66% |
About 62% of Huadong Medicine's investor base is looking to short. The analysis of overall sentiment of trading Huadong Medicine Co stock suggests that many investors are alarmed at this time. The current market sentiment, together with Huadong Medicine's historical and current headlines, can help investors time the market. In addition, many technical investors use Huadong Medicine stock news signals to limit their universe of possible portfolio assets.
Huadong |
China advances semaglutide biosimilars, Jiuyuan seeks NMPA nod BioWorld Online
Read at news.google.com
 |
Huadong Medicine Fundamental Analysis
We analyze Huadong Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Huadong Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Huadong Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Last Dividend Paid
Last Dividend Paid Comparative Analysis
Huadong Medicine is currently under evaluation in last dividend paid category among its peers. Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
Huadong Medicine Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Huadong Medicine stock to make a market-neutral strategy. Peer analysis of Huadong Medicine could also be used in its relative valuation, which is a method of valuing Huadong Medicine by comparing valuation metrics with similar companies.
Peers
Huadong Medicine Related Equities
| 601398 | Industrial | 0.62 | ||||
| 601988 | Bank of China | 0.57 | ||||
| 600036 | China Merchants | 0.29 | ||||
| 600519 | Kweichow Moutai | 0.34 | ||||
| 601628 | China Life | 0.81 | ||||
| 601939 | China Construction | 0.82 | ||||
| 601857 | PetroChina | 0.95 | ||||
| 601288 | Agricultural Bank | 1.18 | ||||
| 600941 | China Mobile | 2.15 | ||||
| 300750 | Contemporary Amperex | 2.62 |
Complementary Tools for Huadong Stock analysis
When running Huadong Medicine's price analysis, check to measure Huadong Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Huadong Medicine is operating at the current time. Most of Huadong Medicine's value examination focuses on studying past and present price action to predict the probability of Huadong Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Huadong Medicine's price. Additionally, you may evaluate how the addition of Huadong Medicine to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |